Literature DB >> 993132

New pleuromutilin derivatives with enhanced antimicrobial activity.II.Structure-activity correlations.

H Egger, H Reinshagen.   

Abstract

Structural modification of the antibiotic pleuromutilin has afforded several derivatives with considerably enhanced activity against bacteria and mycoplasmas, and has permitted conclusions to be reached about structure-activity relationships. The carbonyl group in the five-membered ring and the hydroxyl group at C11 seem to be essential for activity. The vinyl group can be hydrogenated without loss of activity. Chemical modification at C14 offers the most possibilities for achieving the best activity and solubility properties. Mutilin, and other compounds with a free OH at C14, are inactive. It was shown that mutilin esters of substituted thioglycolic acids had distinctly superior MIC values, especially in combination with a tertiary amino group in the side chain, the latter group of derivatives having MIC values better than pleuromutilin by a factor of more than 10. Further variation within this group led to the development of 14-deoxy-14-[(2-diethylaminoethyl) thioacetoxy]-mutilin hydrogen fumarate (81.723 hfu, tiamulin) for extensive investigation of its chemotherapeutic potential.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 993132     DOI: 10.7164/antibiotics.29.923

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  16 in total

1.  A concise synthesis of the molecular framework of pleuromutilin.

Authors:  Junjia Liu; Stephen D Lotesta; Erik J Sorensen
Journal:  Chem Commun (Camb)       Date:  2010-11-16       Impact factor: 6.222

2.  Activity of retapamulin against Streptococcus pyogenes and Staphylococcus aureus evaluated by agar dilution, microdilution, E-test, and disk diffusion methodologies.

Authors:  Glenn A Pankuch; Gengrong Lin; Dianne B Hoellman; Caryn E Good; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

3.  Structural insights into species-specific features of the ribosome from the pathogen Staphylococcus aureus.

Authors:  Zohar Eyal; Donna Matzov; Miri Krupkin; Itai Wekselman; Susanne Paukner; Ella Zimmerman; Haim Rozenberg; Anat Bashan; Ada Yonath
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-13       Impact factor: 11.205

4.  Fixing the Unfixable: The Art of Optimizing Natural Products for Human Medicine.

Authors:  Audrey E Yñigez-Gutierrez; Brian O Bachmann
Journal:  J Med Chem       Date:  2019-04-26       Impact factor: 7.446

Review 5.  The challenge of converting Gram-positive-only compounds into broad-spectrum antibiotics.

Authors:  Michelle F Richter; Paul J Hergenrother
Journal:  Ann N Y Acad Sci       Date:  2018-02-15       Impact factor: 5.691

6.  Development of a Modular Synthetic Route to (+)-Pleuromutilin, (+)-12-epi-Mutilins, and Related Structures.

Authors:  Mingshuo Zeng; Stephen K Murphy; Seth B Herzon
Journal:  J Am Chem Soc       Date:  2017-11-02       Impact factor: 15.419

7.  Expanding the pleuromutilin class of antibiotics by de novo chemical synthesis.

Authors:  Stephen D Lotesta; Junjia Liu; Emma V Yates; Inna Krieger; James C Sacchettini; Joel S Freundlich; Erik J Sorensen
Journal:  Chem Sci       Date:  2011-04-14       Impact factor: 9.825

8.  Induced-fit tightens pleuromutilins binding to ribosomes and remote interactions enable their selectivity.

Authors:  Chen Davidovich; Anat Bashan; Tamar Auerbach-Nevo; Rachel D Yaggie; Richard R Gontarek; Ada Yonath
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-08       Impact factor: 11.205

9.  Design and Synthesis of Molecular Scaffolds with Anti-infective Activity.

Authors:  Junjia Liu; T Aaron Bedell; Julian G West; Erik J Sorensen
Journal:  Tetrahedron       Date:  2016-01-28       Impact factor: 2.457

10.  Ribosomal binding region for the antibiotic tiamulin: stoichiometry, subunit location, and affinity for various analogs.

Authors:  G Högenauer; C Ruf
Journal:  Antimicrob Agents Chemother       Date:  1981-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.